M
Muin J. Khoury
Researcher at Centers for Disease Control and Prevention
Publications - 523
Citations - 40286
Muin J. Khoury is an academic researcher from Centers for Disease Control and Prevention. The author has contributed to research in topics: Population & Public health. The author has an hindex of 105, co-authored 512 publications receiving 37434 citations. Previous affiliations of Muin J. Khoury include United States Department of Health and Human Services & Université de Montréal.
Papers
More filters
Journal ArticleDOI
Are offspring of women with hereditary hematologic disorders at increased risk of congenital cardiovascular malformations
TL;DR: Data from a nationwide birth defects monitoring program covering about 2.9 million births in the United States between 1982 and 1988 suggest an excess risk of CCM among offspring of women with selected HHD, and further studies are needed to explore these findings.
Book ChapterDOI
Human genome epidemiology: The road map revisited
Muin J. Khoury,Sara Bedrosian,Marta Gwinn,Julian Little,Julian Little,Julian P T Higgins,John P. A. Ioannidis +6 more
Journal ArticleDOI
Sample size requirements to detect the effect of a group of genetic variants in case-control studies
TL;DR: A simple method for determining approximate sample sizes required to detect the average joint effect of a group of genetic variants in a case-control study for multiplicative models is presented.
Journal Article
Predictive value of testing for multiple genetic variants in multifactorial
Cécile Janssens,Muin J. Khoury +1 more
TL;DR: In this article, the authors translate ethical, legal, and social issues that apply to predictive genetic testing for monogenic diseases may not be relevant for the prediction of multifactorial disorders in genomic medicine.
Journal ArticleDOI
Utility before business.
TL;DR: Today, enthusiasm for genomics far outstrips the relatively modest, albeit increasing, number of clinical scenarios for which it provides established health benefits; the clinical usefulness should be foremost; and the downstream medical and financial consequences of testing should be considered.